Clinical Trials Update: Sept. 27, 2006
Epilepsy HIV Infections Depression (Major/Severe)
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This trial will assess the effectiveness and safety of a study drug in people with epileptic seizures. Volunteers at least 13 who have been diagnosed with epilepsy, have partial or PGTC seizures, and have been treated with a stable regimen of one or two AED(s) for at least four weeks may be eligible.
The research sites are located in the United States, Mexico, and Puerto Rico.
This study will assess the antiviral activity and safety of bevirimat (PA103001-04) in HIV patients that are failing an antiretroviral treatment regimen. Volunteers 18-65 with documented HIV-1 infection who have been on a stable antiretroviral therapy for at least eight weeks may qualify. People with uncontrolled hypertension, a history of seizures (excluding pediatric febrile seizures), migraines, cluster and/or chronic headaches, cerebrovascular accident (CVA), or transient ischemic attack (TIA) will not be eligible.
The research sites are located across the United States.
Have you been feeling depressed, less motivated, worthless, helpless, or hopeless? If you have some or all of these symptoms, are 18 to 65, and are otherwise in good health, you may qualify for this study of an experimental medication to treat major depression.
The research site is in Poughkeepsie, NY.
Copyright 2006 Thomson CenterWatch. All rights reserved.